Further, because of the protective effects of ACE2 on chronic underlying diseases and ARDS, the development of therapeutic enhancers of ACE2 activity, such as diminazene aceturate (DIZE) 103, which are currently used as antiparasitic drugs, has been proposed for the treatment of COVID-19 patients in the late stages of disease 104. Here, ACE2 is linked to acute respiratory distress syndrome.